We have worked with Ava for some time now and have really enjoyed the process of creating publicity for their fertility tracking bracelet.
We were given the task to publicise the ground-breaking results of their latest clinical trial which confirmed that five physiological signals actually change during a women’s menstrual cycle – and that by measuring these signals women will be able to identify when they are at their most fertile.
This confirmed Ava’s growing reputation as a leader in the femtech sector. Its bracelet is the only fertility device that measures these five key signals (resting pulse rate, breathing rate, wrist skin temperature, heart rate variability and skin perfusion). It detects the very first signs that the fertile window is beginning and also confirming when it ends, providing the wearer with a (real time) forecast of her five most fertile days with 90% accuracy.
Because all other fertility monitoring products only measure one parameter – we knew we had to aim high with the news.
So, we went to Forbes – with the feature clearly contrasting the depth of science and research behind Ava’s product with that of rivals … including Apple!
We also had additional results alongside the research news with articles covering topics such as the future of healthcare, the best femtech products and inspirational women.
These titles included: We Are Tech Women, The Evening Standard, Women of Wearables, Belfast Telegraph, a PA article, Health Europa, Compelo and The Times / Raconteur Media.
All previous coverage we have secured for the Ava bracelet can be seen here.
